Navigation Links
Cardio3 BioSciences Raises EUR13.7 Million in Series B Fundraising and Grant Funding
Date:1/19/2009

anies in Wallonia at the cutting-edge of technology by providing financing solutions in a difficult financial environment."

About Cardio3 BioSciences

Cardio3 BioSciences is a leading Belgian biotechnology company specialising in stem cell-based therapies for the treatment of cardiovascular disease. The Company's lead product, C-Cure is a highly innovative approach to the treatment of heart failure, one of the world's most pressing unmet medical needs. Based on a strategy developed by Cardio3 BioSciences' founders and leveraging technology from Mayo Clinic, C-Cure allows the differentiation of a patient's own cells into 'cardiopoeitic' cells which grow into new heart cells and repair heart muscle. An international clinical trial of C-Cure sponsored by Cardio3 BioSciences is expected to begin in early 2009.

The Cardio3 BioSciences team has extensive experience in developing and commercialising new pharmaceutical products and medical technologies and the Company's strategy is to drive the clinical development of C-Cure and to market the product itself in major territories.

Cardio3 BioSciences was founded in July 2007 and is based in Mont-Saint-Guibert in the Walloon region of Belgium.

About C-Cure(R)

C-Cure is a second generation cell therapy for the treatment of heart failure that involves taking a patient's own stem cells from bone marrow and through a proprietary culturing technology generating differentiated 'cardiopoeitic' cells which can regenerate damaged heart muscle. Unlike previous cell therapies for this indication, C-Cure is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.

C-Cure draws on the unrivalled understanding of the fundamental science of heart cell development within Cardio3 BioSciences and on technology developed at Mayo Clinic, one o
'/>"/>

SOURCE Cardio3 BioSciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Tandem Diabetes Care®, Inc. (NASDAQ: ... of the t:slim® Insulin Pump, today reported its financial results ... In comparing the second quarter of 2014 to the same ... $10.3 million from $5.5 million , t:slim Pump shipments ... In comparing six months ended June 30, 2014 to ...
(Date:7/31/2014)... SUNNYVALE, Calif., July 31, 2014 Pharmacyclics, Inc. (the ... and recent developments for the quarter ended June 30, 2014. ... Ended June 30, 2014 Revenue Total revenue for the ... $54.7 million for the quarter ended June 30, 2013 primarily ... $109.5 million. Total revenue for the six ...
(Date:7/31/2014)... SAN FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... the second quarter ended June 30, 2014. ... were $301.4 million as compared to $309.1 million at March ... time for Nektar as we look forward to significant milestones ... W. Robin, President and Chief Executive Officer of Nektar. "The ...
Breaking Medicine Technology:Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 2Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 3Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 4Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 5Tandem Diabetes Care Reports Second Quarter 2014 Financial Results 6Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24Pharmacyclics Reports Second Quarter 2014 Results 25Pharmacyclics Reports Second Quarter 2014 Results 26Pharmacyclics Reports Second Quarter 2014 Results 27Pharmacyclics Reports Second Quarter 2014 Results 28Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4
... ANDOVER, Mass., June 23, 2011 Smith & Nephew, Inc., ... SNN ) (London Stock Exchange: SN) announced today ... found in Smith & Nephew,s favor that Arthrex, Inc., (Naples, ... exclusively licensed to Smith & Nephew. The ...
... Mr. Ronald L. Chez, a private investor, filed an amended ... RGEN ) with the SEC. RepliGen Corporation ... integrated company by developing and marketing innovative drugs that deliver ... and gastroenterology.  RepliGen has a core competency in the development ...
Cached Medicine Technology:Smith & Nephew Endoscopy Awarded $85 Million in Patent Infringement Case Against Arthrex, Inc. 2Smith & Nephew Endoscopy Awarded $85 Million in Patent Infringement Case Against Arthrex, Inc. 3
(Date:8/2/2014)... On July 21, 2014, the Johns Hopkins Health System ... the class action lawsuit filed October 24, 2013, ... MM, on behalf of thousands of women who allegedly were ... According to The Baltimore Sun , the $190 million ... physician accused of sexual misconduct. , An investigation prompted by ...
(Date:8/1/2014)... August 02, 2014 Although most people ... their teeth and gums, it is particularly important for ... gum disease in two different ways. Hormones can affect ... difficult for these tissues to receive nutrients essential to ... the body responds to toxins produced by plaque bacteria, ...
(Date:8/1/2014)... The Judicial Panel on Multidistrict Litigation (JPML) ... caused strokes, heart attacks, and other injuries in men ... Kennelly as the transferee judge and ordered what could ... court. , As one of his first organizing acts, ... attorneys who will move the litigation forward on behalf ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Parker Waichman ... rights of victims injured by defective medical devices and ... be recalling its Ethicon surgical power morcellator devices used ... sited concerns involving the spread of cancer associated with ... dated July 31, 2014. , Johnson & Johnson ...
(Date:8/1/2014)... Almost 140 people die every year in accidents ... But there are several simple ways to ... coordinator at Cincinnati Children,s Hospital Medical Center,s Comprehensive ... news release. "As families begin to prepare ... parents and children to go over school bus ...
Breaking Medicine News(10 mins):Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 2Health News:Baltimore Lawyer Steven H. Heisler Urges Victims of OB/GYN Misconduct to Speak Out 3Health News:Midtown Dentistry Renews Call for Women to Look After Their Dental Health 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:Expert Offers School Bus Safety Tips 2
... had been in the forefront, monitoring the Herculean task of ... the documentation of the dealers. // This is being done ... is still in safe custody. 20 teams comprising of officials ... with local civic officials. ,The teams will be ...
... in Hong Kong and China have identified the deadly H5N1 ... markets of Southern China, sparking fears of bird flu pandemic//. ... hosts of the bird flu virus. This however is the ... detected among seemingly healthy chickens. Infected chickens usually die within ...
... 'in'? A new report by the American Medical Association has ... wild (s) ways!// ,A survey of 644 female college ... berserk is their take on having fun in life. Three out ... for outrageous behavior- spring break drinking meant bingeing on booze, getting ...
... for a probable influenza pandemic, and its effects on 2.6 ... concern and at a press conference , Health Minister Philippe// ... the beginning of the epidemic we're able to limit the ... plan ready, to face a worst-case possibility, of the initial ...
... It's been a long haul from a medical college here ... becoming the only Indian-born radiologist// licensed to privately practise in ... in his specialty along the way., ,He sees up ... p.m. and then writes up the reports, a task that ...
... means just tough whole-grain products. The movement has burst out ... are available that would have been unthinkable a few years ... whole-grain muesli, rubbery tofu and tasteless vegetarian cutlets, but times ... of Europe today, you will find organic ice cream and ...
Cached Medicine News:Health News:Healthy, Bird Flu Infected Chickens In Chinese Markets 2Health News:Indian-Born Doctor Diddy Shines In Germany 2Health News:Organic food loses its whole-grain image 2
... a two-piece Titanium (Ti-6Al-4V) screw offered in ... variety of lengths. The two pieces are ... packaged. A single instrument set contains all ... both Standard and Mini Kompressor Compression Screws. ...
... Avanta Total Wrist is designed ... in patients suffering from rheumatoid, ... The implant is designed as ... bone resection and aiding in ...
... Within the last decade KMI® revolutionized the ... the Universal Total Wrist System. We're at ... next generation product, the Universal2. Like the ... the way patients live with debilitating arthritis. ...
... NeedlePunch is a simple, effective instrument to grasp ... FiberWire stitch and loop. The grasping function of ... soft tissue and precisely place a stitch up ... the tissue, all in one quick step. The ...
Medicine Products: